Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous
thromboembolism, arterial thrombosis, and obstetric morbidities in the setting of persistently …

RA is characterized by a systemic inflammatory state, in which immune cells and soluble
mediators play a crucial role. These inflammatory processes resemble those in other chronic …

Background Recent hospital-based studies have suggested a sixfold increased risk of
pulmonary embolism (PE) in rheumatoid arthritis (RA) in the year following admission. We …

Objectives To estimate the overall risk of venous thromboembolism (VTE), pulmonary
embolism (PE) and deep vein thrombosis (DVT) among patients newly diagnosed with RA …

Antiphospholipid antibodies (APLAs) are primarily directed toward phospholipid-binding
proteins and are responsible for thrombotic events. APLAs include anti-β2Glycoprotein I …

Objective To investigate the incidence of noncardiac vascular disease in a community‐
based incidence cohort of patients with rheumatoid arthritis (RA) and compare it to that in the …

Objectives: This study aimed to evaluate the risk of venous thrombosis (VTE) associated with
Janus kinase (JAK) inhibitors in patients diagnosed with immune-mediated inflammatory …

Background Antiphospholipid syndrome (APS) is a systemic autoimmune disorder
characterized by arterial and venous thrombosis or pregnancy morbidity in patients with …

Objective: To scope the current published evidence on cardiovascular risk factors in
rheumatoid arthritis (RA) focusing on the role of autoantibodies and the effect of …

Background The diagnosis of antiphospholipid syndrome (APS) requires the presence of
thrombosis and/or recurrent miscarriages along with one or more anti-phospholipid …